Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

September 2019; 6 (5) EditorialOpen Access

Blood neurofilament light chain at the doorstep of clinical application

David Leppert, Jens Kuhle
First published August 9, 2019, DOI: https://doi.org/10.1212/NXI.0000000000000599
David Leppert
From the Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jens Kuhle
From the Neurologic Clinic and Policlinic, Departments of Medicine, Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland.
MD, PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Blood neurofilament light chain at the doorstep of clinical application
David Leppert, Jens Kuhle
Neurol Neuroimmunol Neuroinflamm Sep 2019, 6 (5) e599; DOI: 10.1212/NXI.0000000000000599

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
948

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Multiples sclerosis (MS) is a chronic progressive disorder of the CNS with inflammatory and neurodegenerative pathomechanisms leading to various degrees of neurologic disability. In the past 2 decades, high-efficacy disease-modifying therapies (DMTs) have become available that lead to near-complete suppression of acute disease activity (relapses, lesion formation) in most patients, and only a small number of patients exhibit an aggressive disease course despite adequate use of DMTs. Here, immunoablation followed by stem cell transplantation (SCT) has emerged in recent years as an efficacious approach to stop acute disease activity, based on the concept of a reset of the immune system. However, DMTs show minimal effect on the course of progression. Accordingly, 30% (7/23) of patients continue to experience clinical progression and additional brain atrophy as its MRI equivalent 12 months after SCT.1

Neurofilaments are intracellular cytoskeletal proteins that are categorized according to their molecular weight in light, medium, and heavy chain types. Neuronal damage results in leaking of this protein into the extracellular space and eventually into CSF and blood. Neurofilament light chain (NfL) has been established in recent years as a biomarker (1) to quantify acute disease activity, (2) to monitor therapy response, and (3) to predict the course of disability and of brain and spinal cord atrophy2,–,6 in pharmacologically treated relapsing-remitting MS (RRMS) and progressive MS (PMS). Based on the strong correlation between CSF and plasma or serum measures, NfL is now at the doorstep to become the first biomarker that is applicable in clinical routine setting for longitudinal measurements based on blood sampling, a minimally invasive procedure.

In this issue of Neurology: Neuroimmunology & Neuroinflammation, Thebault et al.1 used a highly sensitive digital ELISA (single molecule array) to test whether NfL results from pharmacologically treated MS cohorts can be replicated in a patient cohort with aggressive MS that underwent SCT. They found that1 as a retrospective correlation, NfL baseline levels in serum and CSF were associated with referring disability scores and recent prior relapse activity, and2 as a prospective correlation, the above median levels of NfL were found associated with a higher probability for sustained Expanded Disability Status Scale progression and worse outcome of cognitive function and quality of life scores. This was paralleled by higher scores for brain lesional volume and the course of atrophy over an observation period of 36 months, both by categorical and individual patient analysis. A novel finding in their study is that above median NfL levels correlated with the NAA/Cr ratio in MR spectroscopy, a measure of brain-diffuse neuronal loss.3 Although SCT led to a decrease in serum NfL levels in the entire cohort, the patient group that experienced disease progression after SCT had higher serum NfL levels 12 months after intervention than that with stabilized disability. Again, this was paralleled by the correlation of brain white matter atrophy and NfL levels. As no clinical or MRI signs for confounding acute disease activity were observed in this cohort after SCT, NfL levels can be seen as direct reflection of progressive disease. The study of Thebault et al. provides further support for NfL being a biomarker of therapeutic response in both directions, i.e., to assess the effect of an intervention and to indicate insufficient effect, which may qualify NfL as a surrogate trial end point.7

At first glance, the findings of coherent lowering of NfL levels after SCT and predictive capacity of baseline levels for future clinical and MRI features of disease progression seem paradoxical. However, the concept of “therapeutic lag”8 provides an elegant explanation where worsening disability in progressive MS is primed by past inflammation. Hence, the inflammation suppressing activity of DMT or SCT will have no immediate impact on worsening disability over the next 1 or 2 years, as the damage priming progression over this time has already occurred. Hence, all anti-inflammatory therapies will have a lag of translating the decrease of NfL into a clinically measurable result in terms of stabilizing progression in MS over time.

What is the practical application of the current report by Thebault and other studies in pharmacologically treated RRMS and PMS in clinical trials and retrospective cohorts? We envisage that based on its capacity and profile as a biomarker, NfL may be used in the future as an additional paraclinical measure for physicians in charge of therapeutic decisions, both for treatment initiation and modification (figure). NfL will not replace clinical and MRI-based evaluation, but it will shed light on disease activity that escape detection by the standard diagnostic armamentarium.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure Concept for use of serum/plasma NfL for individual therapeutic decision making in MS

DMT = disease-modifying therapy; NfL = neurofilament light chain.

Still, there are important hurdles for the immediate use of serum NfL in routine clinical practice. We lack a database of normal values, particularly on the background of the age dependency of values. Second, there is currently no assay standardization or commutability between the various assay protocols. Efforts are underway to address these points in the coming years. If successful, we envisage NfL to become the first biofluid marker applicable as personalized medicine tool in MS.

Study funding

No targeted funding reported.

Disclosure

The authors report no disclosures. Disclosures available: Neurology.org/NN.

Footnotes

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • See page e598

  • Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Thebault S,
    2. Tessier D,
    3. Lee H, et al
    . High serum neurofilament light chain normalises after haematopoietic stem cell transplant for MS. Neurol Neuroimmunol Neuroinflamm 2019;6:e598. doi: 10.1212/NXI.0000000000000598.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Barro C,
    2. Benkert P,
    3. Grobke S, et al
    . Serum neurofilament light chain correlates with disease activity and predicts clinical and MRI outcomes in MS. Mult Scler J 2017;23:297–298.
    OpenUrl
  3. 3.↵
    1. Berger T,
    2. Stuve O
    . Neurofilament light chain: an important step toward a disease biomarker in multiple sclerosis. Neurology 2019;92:451–452.
    OpenUrl
  4. 4.↵
    1. Disanto G,
    2. Barro C,
    3. Benkert P, et al
    . Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 2017;81:857–870.
    OpenUrl
  5. 5.↵
    1. Khalil M,
    2. Teunissen CE,
    3. Otto M, et al
    . Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 2018;14:577–589.
    OpenUrl
  6. 6.↵
    1. Kuhle J,
    2. Kropshofer H,
    3. Haering DA, et al
    . Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology 2019;92:e1007–e1015.
    OpenUrl
  7. 7.↵
    1. Sormani MP,
    2. Haering DA,
    3. Kropshofer H, et al
    . Blood neurofilament light as a potential endpoint in phase 2 studies in MS. Ann Clin Transl Neurol 2019;6:1081–1089.
    OpenUrl
  8. 8.↵
    1. Giovannoni G,
    2. Cutter G,
    3. Sormani MP, et al
    . Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses. Mult Scler Relat Disord 2017;12:70–78.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

Association of Mediterranean-DASH Intervention for Neurodegenerative Delay and Mediterranean Diets With Alzheimer Disease Pathology

Dr. Babak Hooshmand and Dr. David Smith

► Watch

Related Articles

  • High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS

Topics Discussed

  • Class II
  • Multiple sclerosis
  • Clinical trials Observational study (Cohort, Case control)

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS
    Simon Thebault, Daniel R. Tessier, Hyunwoo Lee et al.
    Neurology: Neuroimmunology & Neuroinflammation, August 09, 2019
  • Clinical/Scientific Notes
    NfL is a biomarker for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia
    Stefanie N. Hayer, Ilona Krey, Christian Barro et al.
    Neurology, September 14, 2018
  • Article
    Neurofilament light chain
    A prognostic biomarker in amyotrophic lateral sclerosis
    Ching-Hua Lu, Corrie Macdonald-Wallis, Elizabeth Gray et al.
    Neurology, May 01, 2015
  • Article
    Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS
    Sinah Engel, Michaela Friedrich, Muthuraman Muthuraman et al.
    Neurology: Neuroimmunology & Neuroinflammation, July 19, 2019
Neurology - Neuroimmunology Neuroinflammation: 10 (6)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise